A Study of Two Approved Drugs in Patients With Osteoarthritis (0966-219)

Merck Sharp & Dohme LLC395 enrolled

Overview

The purpose of this study is to compare the safety and effectiveness of two approved drugs in the treatment of osteoarthritis of the knee.

The duration of treatment is 6 weeks.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

395

Conditions

Osteoarthritis

Interventions

MK0966, rofecoxibDRUG

Comparator: celecoxib, placeboDRUG

Eligibility

Sex: ALLMin age: 40 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Osteoarthritis of the knee which requires treatment with medication for pain relief Exclusion Criteria: * Any known allergy to the study drug

Outcomes

Primary Outcomes

Osteoarthritis (OA) of the knee as measured by Patient Global Assessment of Response to Therapy (PGART) and WOMAC VA 3.0 over 6 weeks of treatment.

Secondary Outcomes

OA of the knee as measured by PGART over 6 wks of treatment.

WOMAC Question #1 over 6 wks of treatment.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.